Malnutrition and Sarcopenia Screening in Chemotherapy Patients
NCT ID: NCT07163286
Last Updated: 2025-09-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
200 participants
OBSERVATIONAL
2025-07-01
2026-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Relationship of Nutritional Status to Chemotherapy Treatment Completion and Outcomes in Cancer Patients
NCT07059598
Nutritional Risk and Mucositis in Patients With Head and Neck Carcinoma Receiving Chemoradiation
NCT00577902
Short-Term Fasting Before Chemotherapy in Treating Patients With Cancer
NCT01175837
Effect of Sarcopenia on the Occurrence of Toxicity Related to Anti-cancer Treatments
NCT06274268
Nutritional Supplements in Improving Quality of Life During First-Line Chemotherapy in Patients With Metastatic Gynecological Cancer
NCT00905658
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Objective: This cross-sectional study aims to evaluate the risk of malnutrition and sarcopenia in solid tumor outpatients receiving chemotherapy. It compares the effectiveness and correlation of PG-SGA, MUST, Nutriscore, and GLIM criteria, and investigates their association with sarcopenia, measured via handgrip strength and CT-based skeletal muscle index at the L3 level.
Methods: Approximately 150 adult cancer patients receiving active outpatient chemotherapy will be assessed. Nutritional status will be evaluated using PG-SGA, MUST, Nutriscore, and GLIM. Sarcopenia will be determined via handgrip strength testing and analysis of CT images. Charlson Comorbidity Index will be used to assess comorbidity burden.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
The study will include approximately 150 adult outpatients diagnosed with solid tumors who are currently receiving chemotherapy. Both early and advanced stage patients of any sex aged 18 and older will be included, provided they are clinically stable and able to participate in the assessments.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosed with a solid tumor (e.g., breast, lung, GI, gynecologic cancers)
* Receiving active outpatient chemotherapy
* Recent abdominal CT scan within the last 3 months or planned
* Provided written informed consent
* Physically and mentally able to complete study procedures
Exclusion Criteria
* Cognitive impairment or mental status preventing participation
* Neuromuscular diseases affecting muscle mass (e.g., myopathy, MND, severe neuropathy)
* Inadequate CT image quality for L3 analysis
* Acute infection or illness within the past month
* Upper limb deformity or severe pain preventing handgrip testing
* Incomplete assessments or withdrawal of consent during the study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Çanakkale Onsekiz Mart University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Şeyma Eroğlu
Oncology Fellowship Dr.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Çanakkale Onsekiz Mart University
Çanakkale, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, Murphy R, Ghosh S, Sawyer MB, Baracos VE. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013 Apr 20;31(12):1539-47. doi: 10.1200/JCO.2012.45.2722. Epub 2013 Mar 25.
Bellanti F, Lo Buglio A, Quiete S, Pellegrino G, Dobrakowski M, Kasperczyk A, Kasperczyk S, Vendemiale G. Comparison of Three Nutritional Screening Tools with the New Glim Criteria for Malnutrition and Association with Sarcopenia in Hospitalized Older Patients. J Clin Med. 2020 Jun 17;9(6):1898. doi: 10.3390/jcm9061898.
Trujillo EB, Kadakia KC, Thomson C, Zhang FF, Livinski A, Pollard K, Mattox T, Tucker A, Williams V, Walsh D, Clinton S, Grossberg A, Jensen G, Levin R, Mills J, Singh A, Smith M, Stubbins R, Wiley K, Sullivan K, Platek M, Spees CK. Malnutrition risk screening in adult oncology outpatients: An ASPEN systematic review and clinical recommendations. JPEN J Parenter Enteral Nutr. 2024 Nov;48(8):874-894. doi: 10.1002/jpen.2688. Epub 2024 Oct 16.
Cederholm T, Jensen GL, Correia MITD, Gonzalez MC, Fukushima R, Higashiguchi T, Baptista G, Barazzoni R, Blaauw R, Coats A, Crivelli A, Evans DC, Gramlich L, Fuchs-Tarlovsky V, Keller H, Llido L, Malone A, Mogensen KM, Morley JE, Muscaritoli M, Nyulasi I, Pirlich M, Pisprasert V, de van der Schueren MAE, Siltharm S, Singer P, Tappenden K, Velasco N, Waitzberg D, Yamwong P, Yu J, Van Gossum A, Compher C; GLIM Core Leadership Committee; GLIM Working Group. GLIM criteria for the diagnosis of malnutrition - A consensus report from the global clinical nutrition community. Clin Nutr. 2019 Feb;38(1):1-9. doi: 10.1016/j.clnu.2018.08.002. Epub 2018 Sep 3.
Arribas L, Hurtos L, Sendros MJ, Peiro I, Salleras N, Fort E, Sanchez-Migallon JM. NUTRISCORE: A new nutritional screening tool for oncological outpatients. Nutrition. 2017 Jan;33:297-303. doi: 10.1016/j.nut.2016.07.015. Epub 2016 Aug 13.
Cho JW, Youn J, Kim EM, Choi MG, Lee JE. Associations of patient-generated subjective global assessment (PG-SGA) and NUTRISCORE with survival in gastric cancer patients: timing matters, a retrospective cohort study. BMC Gastroenterol. 2022 Nov 17;22(1):468. doi: 10.1186/s12876-022-02515-3.
Baracos VE, Martin L, Korc M, Guttridge DC, Fearon KCH. Cancer-associated cachexia. Nat Rev Dis Primers. 2018 Jan 18;4:17105. doi: 10.1038/nrdp.2017.105.
Lee JS, Kim YS, Kim EY, Jin W. Prognostic significance of CT-determined sarcopenia in patients with advanced gastric cancer. PLoS One. 2018 Aug 20;13(8):e0202700. doi: 10.1371/journal.pone.0202700. eCollection 2018.
Hebuterne X, Lemarie E, Michallet M, de Montreuil CB, Schneider SM, Goldwasser F. Prevalence of malnutrition and current use of nutrition support in patients with cancer. JPEN J Parenter Enteral Nutr. 2014 Feb;38(2):196-204. doi: 10.1177/0148607113502674.
Pressoir M, Desne S, Berchery D, Rossignol G, Poiree B, Meslier M, Traversier S, Vittot M, Simon M, Gekiere JP, Meuric J, Serot F, Falewee MN, Rodrigues I, Senesse P, Vasson MP, Chelle F, Maget B, Antoun S, Bachmann P. Prevalence, risk factors and clinical implications of malnutrition in French Comprehensive Cancer Centres. Br J Cancer. 2010 Mar 16;102(6):966-71. doi: 10.1038/sj.bjc.6605578. Epub 2010 Feb 16.
Bullock AF, Patterson MJ, Paton LW, Currow DC, Johnson MJ. Malnutrition, sarcopenia and cachexia: exploring prevalence, overlap, and perceptions in older adults with cancer. Eur J Clin Nutr. 2024 Jun;78(6):486-493. doi: 10.1038/s41430-024-01433-9. Epub 2024 Apr 5.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COMU-FNO-3
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.